COLL vs SUPN
COLL: A diversified biopharmaceutical firm managing a portfolio of ADHD treatments and chronic pain management therapies. SUPN: A CNS-focused biopharmaceutical company developing and commercializing treatments for epilepsy, ADHD, and other neurological disorders.
Side-by-side fundamentals
| Metric | COLL | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $22.11 | $42.14 | |
| Market cap | $720M | $2.4B | |
| P/E as of 2026-10-08 | 19.84 | n/a | |
| Net margin FY2025, SEC XBRL | +8.1% | -5.4% | COLL higher |
| Gross margin FY2025, SEC XBRL | +59.3% | n/a | |
| Operating margin FY2025, SEC XBRL | +23.0% | -8.7% | COLL higher |
| ROE FY2025, SEC XBRL | +20.8% | -3.6% | COLL higher |
| ROA FY2025, SEC XBRL | +3.8% | -2.7% | COLL higher |
| Debt / equity as of 2026-09-03 | 3.89 | 0.00 | SUPN lower |
| Revenue growth (YoY) as of 2026-09-03 | +14.3% | +24.9% | SUPN higher |
| Revenue CAGR (3y) SEC XBRL | +18.9% | +2.5% | COLL higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.52 | 0.50 | |
| 1-year return as of 2026-10-08 close | -33.3% | -12.2% | SUPN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.